CEO of Compass Pathways Buys 175,000 Shares, Boosting Stake by 17% to Signal Confidence in Biotech Future
CEO Nath Kabir’s March 2026 share purchase at Compass Pathways shows rising confidence amid volatile stock; investors weigh FDA‑review prospects.
3 minutes to read







